Home// - C5a antibody to treat COVID-19 pneumonia
Are you sure you want to exit?
Any unsave changes will be lost.
C5a antibody to treat COVID-19 pneumonia
InflaRx N.V.
Category
Case Management
Country
Germany, Europe
Description
InflaRx N.V. is testing IFX-1, a monoclonal anti-human complement factor C5a antibody currently under development as treatment for inflammatory conditions and COVID-19 pneumonia.